Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of ECC5004 Formulations in Healthy Participants
NCT06268145Phase 1Completed
- Sponsor
- Eccogene
- Start
- Feb 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elecoglipron in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eccogene. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration, Area Under the Concentration-Time Curve From Time Zero to Infinity and 2 more. Started Feb 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06268145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268145.